YL-413

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameYL-413
Drug Alias NameYL413YL-413
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitorsTubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase ITubulin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMediLink Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMediLink Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A